Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds

Oncogenic RAS proteins are important for driving tumour formation, and for maintenance of the transformed phenotype, and thus their relevance as a cancer therapeutic target is undeniable. We focused here on obtaining peptidomimetics, which have good pharmacological properties, to block Ras–effector...

Descripción completa

Detalles Bibliográficos
Autores principales: Pallara, Chiara, Cabot, Debora, Rivas, Josep, Brun, Sonia, Seco, Jesús, Abuasaker, Baraa, Tarragó, Teresa, Jaumot, Montserrat, Prades, Roger, Agell, Neus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499927/
https://www.ncbi.nlm.nih.gov/pubmed/36138080
http://dx.doi.org/10.1038/s41598-022-19703-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499927/
https://www.ncbi.nlm.nih.gov/pubmed/36138080
http://dx.doi.org/10.1038/s41598-022-19703-6

Ejemplares similares